318 results about "White blood cell number" patented technology

Peripheral blood leucocytes incubated with a semi-synthetic phage antibody library and fluorochrome-labeled CD3 and CD20 antibodies were used to isolate human single chain Fv antibodies specific for subsets of blood leucocytes by flow cytometry. Isolated phage antibodies showed exclusive binding to the subpopulation used for selection or displayed additional binding to a restricted population of other cells in the mixture. At least two phage antibodies appeared to display hithereto unknown staining patterns of B lineage cells. This approach provides a subtractive procedure to rapidly obtain human antibodies against known and novel surface antigens in their native configuration, expressed on phenotypically defined subpopulations of cells. Importantly, this approach does not depend on immunization procedures or the necessity to repeatedly construct phage antibody libraries.

The invention discloses the use of ursane type triterpenoid saponin in preparing medicine for increasing leucocyte and / or platelet which has a general formula (I), the invention also provides a pharmaceutical composition having the action of increasing human leucocyte and / or platelet, which contains ursane type triterpenoid saponin composition having a general formula (I), and pharmaceutically acceptable salts.

1. A method for classifying and counting leukocytes, which comprises:(1) a step of staining cells in a sample obtained from a hematological sample by treatment with a hemolytic agent, with a fluorescent dye;(2) a step of introducing the sample containing the stained cells into a flow cytometer to measure first scattered light, second scattered light different from the first scattered light and fluorescence of the respective cells;(3) a step of obtaining scattered light peak intensities and scattered light widths of the respective cells based on the measured first scattered light, obtaining scattered light intensities of the respective cells based on the measured second scattered light, and obtaining fluorescece intensities of the respective cells based on the measured fluorescence light;(4) a step of classifying the cells into a first group and a second group based on the scattered light peak intensities and the scattered light widths, the first group including leukocytes and second group including platelet clumps;(5) a step of classifying the leukocytes included in the first group into at least lymphocytes, monocytes and granulocytes based on the scattered light intensities and the fluorescence intensities; and(6) a step of counting the classified lymphocytes, the classified monocytes and the classified granulocytes.

The invention discloses a reagent for hemocyte analyzers, which is prepared from diluent, hemolytic agent, sheath flow liquid and cleaning fluid. Compared with the prior art, the invention changes the actual state of long-term dependence on import of the reagent for hemocyte analyzers in China, and is produced and sold in China, thereby greatly reducing the production cost; the hemolytic agent in the reagent does not contain cyanogen, thereby greatly reducing the injury to health of the personnel and experiment operators in manufacturing factories, and avoiding the environment pollution of prussiates; the reagent is especially suitable for the CD3700 / 3500, CD3000 and CD3200 differential count full-automatic hemocyte analyzers of Abbott Laboratories in America, and the hemolytic agent A750test indicates the reagent achieves the ICSH standard; and the correlation coefficients of leucocyte, erythrocyte, hemoglobin, thrombocyte and the like relative to the imported ABBOTT CELL-DYN3700 / 3500 reagent are respectively greater than 0.95.

The invention discloses a nutritional composition for promoting the proliferation of hematopoietic stem cells and the synthesis of haemoglobin. The invention is characterized in that the invention comprises raw materials and the proportion by weight as follows: 90 to 110 nucleotide, 20 to 30 parts of arginine, 20 to 30 parts of lysine, 10 to 20 parts of cysteine, 25 to 35 parts of glycin, 20 to 30 parts of histidine, 110 to 130 parts of lecithin, 50 to 70 parts of cephalin, 0.4 to 0.6 parts of vitamin E, 5 to 7 vitamin C, 0.02 to 0.04 parts of folacin, 0.05 to 0.07 parts of vitamin B2, 0.07 to 0.08 vitamin B6, 0.0001 to 0.0002 parts of vitamin B12, 0.5 to 1.5 parts of ferrum, 0.5 to 0.7 parts of zinc, 0.4 to 0.6 parts of manganese, 14 to 16 parts of boxthorn amylase, and 14 to 16 parts of grapestone aqueous extract. The invention can evidently improve the quantity of hemoglobins (Hb), red blood cells (RBC), white blood cells (WBC) and blood platelets (Plt) in the blood, can stimulate the proliferation of the marrow hematopoietic stem cells to lead the hematopoietic stem cells to be evidently increased, can evidently improve the number of mitochondrion in the cell and have obvious recovery function to the damage of liver and spleen.

A blood specimen processor by means of which blood specimens are collected into a collection tube containing an anticoagulant and a molded buoy of predetermined density between 1.045 and 1.084 with an embedded water swellable o-ring that expands to form a robust seal in a leucocyte density gradient between the buoy's outer surface and tube's inner surface. The buoy is made of a first resin and a second resin, the first resin having a lower density than the second resin, the first resin and the second resin being present in such amounts and relative proportions so that the body has an overall density between 1.045 and 1.084 and preferably, a center of gravity below a geometric center of the body. When the blood specimen contained in the processor is centrifuged, the buoy is thrust through the separating blood and the developing interface of erythrocytes, leucocytes, and plasma. A reproducible gradient develops that builds a reproducible buffy coat ring around the upper trough at the junction of the edge of the separator buoy and the tube wall. The relative proportions of resin are controlled to create a separator buoy of a desired density so that after centrifugation the buffy coat or other cells of interest will be above the water swellable o-ring.

The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.

The invention provides a method for eliminating HIV in human blood and a device for treating AIDS with non-pharmacotherapy. The method includes (1) pumping the blood containing HIV virus into a soft thin plastic tube while adding air through a T-tube at a definite frequency so that the blood is evenly divided into very small blood droplets (2) introducing the small blood droplets into a screw-shaped quartz tube and exposing the quartz tube under a definite dosage of radiation to kill the HIV virus in the blood droplets is (3) collecting the treated blood in a storage bottle. Results show that after the HIV infected blood is divided into very small blood droplets and is irradiated with a definite dosage of ultraviolet (253.7 nm) for 90 seconds, more than 92% HIV loads in the blood is eliminated, while the lymphocyte (CD4+), erythrocyte, leucocyte and haemoglobin remain almost unchanged.

The invention provides a circulating tumor cell separation device adopting combined field flow separation. The circulating tumor cell separation device comprises an upper cover plate, a channel plate and a substrate plate from top to bottom; a two-step separation method comprising the field flow separation and specific molecular affinity identification is adopted, wherein the field flow separation adopts an acoustic surface wave driving mode and a dielectrophoresis driving mode, horizontal cell grouping migration and cell layering in a vertical plane are realized respectively, and erythrocytes are preliminarily separated from other cell populations; a residual leucocyte mixed liquid passes through a cell recognition area, circulating tumor cells are fixed in the recognition area by recognition ligands, and a tumor cell sample is acquired through releasing operation finally. The device can rapidly realize circulating tumor cell separation without marks, has great significance in the aspects of patient's disease diagnosis, therapy monitoring, pathological research and the like, and can be used for a separation process of other cells, macromolecular protein and micro-particles.

A platelet collecting apparatus 1 comprises a centrifugal separator 20 possessing a rotatable rotor 142 ; a first line 21 for allowing the flow of the blood entering the centrifugal separator 20; a second line 22 for allowing the flow of the blood emanating from the centrifugal separator, a plasma collecting bag 25 connected to the first line 21 and the second line 22 so as to collect the plasma emanating from the centrifugal separator 20 and return the collected plasma to the centrifugal separator 20, a platelet collecting bag 26 connected to the second line 22 so as to collect the platelets emanating from the centrifugal separator 20, a blood delivering pump 11 disposed in the first line 21, and a controller 13 for controlling the operation of the rotor of the centrifugal separator 20 and the operation of the blood delivering pump 11. The controller 13 is endowedwith a function of varying the rotational frequency of the rotor 142 during the course of blood collection in conformity with the amount of the blood entered into the centrifugal separator 20 via the first line 21. The invention provides a platelet collecting device with minimal inclusion of leucocyte and having high sampling efficiency of platelet.